Webinar Date/Time: Tue, Mar 14, 2023 11:00 AM EDT
A case study example of study design using the latest tools and methodologies. Learn how you can complete your study potentially quicker and with fewer subjects while increasing probability of trial success.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1568893&tp_key=ed851ed0c6
Event Overview:
Three Key Take-aways:
Speakers
Kal Chaudhuri
Principal, AI/ML Applications & IQVIA Trial Designer
Kal currently leads SOMS & ITD products for IQVIA. His experience is in Artificial Intelligence & Machine Learning (AIML) and new product development and global launch. His specialty is in integrating clinical trial and real-world data sources to discover insights using AIML platforms & algorithms. These methodologies can be used for disease detection and personalized treatment.
Kal brings over 25 years of experience leading technology and business. Kal has worked extensively across technology enabled solutions, services, product life cycle management from organizational & process design, marketing & product management in healthcare and technology services through strategic partnership management & regulatory approval. Kal’s experience prior to IQVIA include leading portfolio transformation for Ricoh, leading health imaging & cancer detection products at Siemens and a variety of other roles.
Eric Groves
VP Strategic Drug Development Design and Delivery innovation
IQVIA
Dr. Groves is Board Certified, in oncology and internal medicine with 32+ years of experience in drug development as corporate officer/senior manager, clinician and researcher. Noteworthy are his accomplishments in clinical and preclinical development, research and general management, for agents with oncologic, infectious disease, immunologic, dermatologic and pain therapy applications. At IQVIA, Dr Groves has provided drug development guidance to a wide variety of clients both small biotech and large pharma. Dr. Groves received his B.S. degree from Massachusetts Institute of Technology and his Ph.D. in physics from the University of Pennsylvania. He earned his M.D. at the University of Miami and completed an internal medicine residency followed by a National Cancer Institute oncology fellowship.
Eva Miller
Director, Biostatistics / CSDD, IQVIA Decision Sciences
IQVIA
Eva currently serves as a thought leader and consultant in statistical methodology for clinical trial design, provide strategic guidance to clients. She specializes in innovative, complex trial designs, adaptive designs, and development of master protocols. She also serves as a member of data monitoring committees, either as blinded or unblinded statistician and support sponsors through the statistical process in interacting with regulatory authorities.
Eva has over 30 years’ experience as statistical science expert in healthcare, pharmaceutical, biotech and start-up industries, non-profit organizations, and academia. Prior to joining IQVIA in January 2022, held leadership positions of increasing responsibility at Cytel, PRA, Syneos, ICON, and ALMAC and consulting roles at Merck, Pfizer, Bristol Myers Squibb, and several biotechs. Before I served as biostatistician /epidemiologist in the NJ Health Dept and psychometrician at the NJ Education Dept. Eva has also authored/co-authored over 100 publications in peer-reviewed journals, presented on innovative & adaptive designs, various statistical methods at conferences in US, Europe.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1568893&tp_key=ed851ed0c6
In Focus: Addressing the Health Literacy Roadblock in Patient Recruitment
Published: November 15th 2024 | Updated: November 15th 2024With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.